DiviTum®TKa Ongoing Research
Ongoing research
DiviTum®TKa is being evaluated in several research studies to evaluate its performance in monitoring metastatic breast cancer and in other tumor types, in conjunction with a number of cell cycle regulating therapeutic regimens.
MONITORING ENDOCRINE THERAPIES
S0226
Investigators: SWOG
MONITORING ET + CDK 4/6 INHIBITORS
PYTHIA
Investigators: IBCSG/BIG
RESISTANCE TO AROMATASE INHIBITORS + CDK 4/6 INHIBITORS
Investigators: University of Nebraska and Washington University, St Louis
EARLY PROGRESSION ON CDK 4/6 INHIBITORS
PROMISE
Investigators: Mayo Clinic
MONITORING PALBOCICLIB + PACLITAXEL THERAPY
Investigators: University of Pennsylvania
DETERMINANTS OF RESISTANCE TO FIRST-LINE THERAPY WITH AN AI AND PALBOCICLIB FOR HR+ MBC
Investigators: Johns Hopkins
PERSONALIZED DISEASE MONITORING IN METASTATIC BREAST CANCER
Christie Hospital, UK
NEOADJUVANT RESPONSE-GUIDED TREATMENT OF SLOWLY PROLIFERATING HORMONE RECEPTOR POSITIVE TUMORS (PREDIX LUMA)
Karolinska University Hospital, Sweden